LLY — Claude Opus 4.8

I'll research LLY before writing the preview. Let me gather recent filings, transcripts, news, and price data.Let me read the most recent quarter's earnings materials and check for recent analyst/oral-drug news.Let me pull the year-ago Q2 2025 release for comparison and check recent news for the TRIUMPH-1 readout and consensus expectations.Let me check consensus expectations and any latest news before writing.# Eli Lilly (LLY) — Q2 2026 Earnings Preview Report date: Wednesday, August 5, 2026 (before market open) · Event: 2026 Q2 Earnings Call

1. Setup Into the Print

Lilly comes into this quarter as the ~$1 trillion incretin bellwether, but the stock has cooled off recently. Shares closed at $1,115.72 on Aug 4, down roughly 9% from their late-June peak near $1,230 (June 29) and essentially flat-to-modestly positive year-to-date (started 2026 near $1,080). The stock has drifted lower in the days directly ahead of the print (~$1,155 on Jul 30 → ~$1,116 on Aug 4), so expectations are elevated but sentiment is not euphoric.

The bar is high for a reason: Q1 2026 was a blowout. Revenue grew 56% to $19.8 billion, beating consensus of ~$17.6B, and non-GAAP EPS of $8.55 crushed the ~$6.66 estimate. Management raised full-year revenue guidance by $2B to $82–85B and non-GAAP EPS to $35.50–37.00. After a beat that large, the key question for Q2 is not whether Lilly grows, but whether it can deliver enough upside to justify a ~12x forward-revenue multiple (versus large-cap pharma peers closer to 5x) and support another guidance raise.

Year-ago comparison base (Q2 2025): - Total revenue: $15.56B (+38% y/y at the time) - Non-GAAP EPS: $6.31 - Mounjaro: $5.20B | Zepbound: $3.38B

For context on the trajectory: Q4 2025 revenue was ~$19.3B with Mounjaro at ~$7.4B and Zepbound ~$4.3B; Q1 2026 Mounjaro was $8.66B and Zepbound $4.16B. The full-year guide midpoint (~$83.5B, ~28% growth) implies continued sequential strength — Street chatter points to the combined Mounjaro/Zepbound franchise potentially topping $13B for the quarter.

2. The Numbers That Matter Most

Metric	Q2 2025 (actual)	What to watch in Q2 2026
Total revenue	$15.56B	Sustained ~40%+ growth; magnitude of any beat vs. the ~28% FY guide
Non-GAAP EPS	$6.31	Watch acquired IPR&D drag from a busy BD quarter
Mounjaro (WW)	$5.20B	U.S. price/volume split + international ramp (>55 countries)
Zepbound (U.S.)	$3.38B	Self-pay mix (~45% of scripts, ~55% of NRx in Q1) and net price
Gross margin (non-GAAP)	85.0%	Trending down (82.6% in Q1) on lower realized prices
Guidance	—	Third consecutive raise? Or a "hold" given macro/pricing

Pricing is the swing factor. Management reiterated a low-to-mid-teens price headwind for the full year, driven by the MFN agreement with the U.S. administration, China NRDL inclusion for Mounjaro, and lower LillyDirect self-pay prices. In Q1, U.S. price fell 7% (would have been ~10% ex a one-time rebate adjustment). Investors have largely accepted that Lilly is trading price for expansionary volume — but any commentary suggesting price erosion is steeper than expected could pressure the multiple.

3. Foundayo (orforglipron) — The First "Real" Launch Quarter

This is the single most-watched line item. The oral GLP-1 pill was FDA-approved for obesity and became broadly available on April 9, so Q2 is the first full quarter of the launch. Going in, remember management framed the ramp as deliberately gradual:

Q1 exit metrics: ~20,000+ patients treated, >8,000 prescribers (one-third new to oral GLP-1s), ~80% of scripts "new-to-class."
Access unlocks during Q2: commercial coverage at 2 of the 3 largest PBMs (mid-May) and the Medicare GLP-1 Bridge program starting July 1 ($50/month copay, potentially millions of eligible seniors).
Full DTC/TV advertising begins in Q3 — so Q2 numbers will precede the biggest awareness push. Don't over-read a modest Q2 revenue figure; the setup is back-half weighted.

Also watch for confirmation of the U.S. type 2 diabetes submission (guided for late Q2), which would open a second, larger indication.

4. Pipeline Catalysts — Retatrutide Is the Story

Beyond the base business, this print sits amid meaningful pipeline momentum:

Retatrutide (triple agonist): Lilly's next-gen obesity injectable. TRIUMPH-1 top-line (80-week obesity study) was guided for "later this quarter," and the company has now confirmed a regulatory filing in Q1 2027, with data showing ~28% average weight loss at the highest dose. Any additional detail on the retatrutide package and TRIUMPH readouts is a potential catalyst.
Positive Phase 3 breadth in Q1: orforglipron ACHIEVE-4 CV outcomes; Jaypirca in CLL (4th positive Phase 3); Ebglyss pediatric AD and every-8-week dosing under review; Taltz + Zepbound combos.
Non-incretin engines growing fast: Immunology/Oncology/Neuroscience key products grew 160% y/y in Q1 (Jaypirca, Ebglyss, Kisunla, Inluriyo, Omvoh). Watch whether this diversification narrative continues to build.

5. Business Development & EPS Optics

Lilly has been aggressively deploying its swelling cash flow (~$17B excess expected this year). Recent deals include Atai/AtaiBeckley (psychedelics, up to ~$3.8B, announced mid-July), plus Orna, Centessa, Kelonia, Ajax, and Ventyx earlier in the year. Two implications for the print:

Acquired IPR&D charges can be a meaningful, lumpy drag on reported/non-GAAP EPS (Q1 included $0.52). Guidance excludes IPR&D incurred after the guidance date, so a headline "miss" driven by deal charges should be looked through.
Capital allocation scrutiny is rising — with the stock expensive, buybacks are less accretive, so investors will want to see BD discipline and strategic logic (neuroscience, immune reset, sleep-wake).

6. Key Risks / Overhangs

Novo Nordisk litigation: Novo sued Lilly (July) alleging false advertising on Zepbound/Mounjaro dose comparisons and is seeking a preliminary injunction to pull the ads. A ruling or corrective-advertising requirement could disrupt DTC campaigns — expect analyst questions on the call.
Pricing/reimbursement policy: MFN implementation, Medicaid access losses in some states (a high-single-digit drag on Q1 Zepbound scripts), and the durability of Part D obesity coverage beyond the 2027 Bridge window.
Competitive dynamics: Generic semaglutide entry internationally (so far stimulating the market per management) and Novo's higher-dose products.
Valuation/expectations risk: After two straight blowouts, a mere in-line quarter could disappoint a stock priced for perfection.

7. Bottom Line — What Would Move the Stock

Bull case for the print: Combined tirzepatide franchise well above ~$13B, U.S. Zepbound net price holding up better than feared, an early-but-encouraging Foundayo trajectory, and a third consecutive guidance raise.

Bear case: Steeper-than-guided price erosion, a soft/ambiguous Foundayo launch read, IPR&D-driven EPS noise, or cautious commentary on the Novo injunction and 2027 Medicare access.

Net: The fundamental momentum is exceptional and diversifying, but with the stock off its highs and richly valued, the reaction likely hinges on (1) the price/volume split on tirzepatide, (2) qualitative Foundayo launch signals ahead of the Q3 DTC push, and (3) whether management again raises the full-year outlook. Mark the December 7, 2026 Investment Community Meeting as the next big-picture catalyst after this print.

Sources: Lilly Q1 2026 and Q2 2025 earnings releases and transcripts; company FY2026 guidance; recent news coverage (CNBC, Reuters, Barron's, WSJ) on Foundayo/Medicare Bridge, retatrutide filing plans, the Novo Nordisk advertising lawsuit, and the Atai acquisition; and Finnhub daily price data through Aug 4, 2026. Figures are non-GAAP unless noted. This is an informational preview, not investment advice.